Literature DB >> 16517714

Superior protective and therapeutic effects of IL-12 and IL-18 gene-transduced dendritic neuroblastoma fusion cells on liver metastasis of murine neuroblastoma.

Hisae Iinuma1, Kota Okinaga, Ryoji Fukushima, Tsuyoshi Inaba, Kota Iwasaki, Akira Okinaga, Ichiro Takahashi, Michio Kaneko.   

Abstract

Fusion vaccine of dendritic cells (DCs) and tumor cells has the advantage of inducing an immune response against multiple tumor Ags, including unknown tumor Ags. Using the liver metastasis model of C1300 neuroblastoma cells, we assessed the protective and therapeutic effects of fusion cells transduced with the IL-12 gene and/or the IL-18 gene. Improving the fusion method by combining polyethylene glycol and electroporation increased loading efficiency. In the A/J mice vaccinated with fusion cells modified with the LacZ gene (fusion/LacZ), IFN-gamma production and CTL activity increased significantly compared with that of DCs/LacZ, C1300/LacZ, or a mixture of the two (mixture/LacZ). With the transduction of IL-12 and IL-18 genes into the fusion cells (fusion/IL-12/IL-18), the level of IFN-gamma increased more than five times that of other fusion groups. In addition, NK cell activity and CTL activity increased significantly compared with that of mixture/LacZ, fusion/LacZ, DC/LacZ, or C1300/LacZ. In the protective and therapeutic studies of fusion cell vaccine, mice vaccinated with fusion/LacZ, fusion/IL-12, fusion/IL-18, or fusion/IL-12/IL-18 showed a significant decrease in liver metastasis and a significant increase in survival compared with mice given a mixture/LacZ, DCs/LacZ, or C1300/LacZ. In particular, the mice receiving fusion/IL-12/IL-18 vaccine showed a complete protective effect and the highest therapeutic effects. The present study investigates the improved loading efficiency of fusion cells and suggests that the introduction of IL-12 and IL-18 genes can induce extremely strong protective and therapeutic effects on liver metastasis of neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517714     DOI: 10.4049/jimmunol.176.6.3461

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Cancer vaccine by fusions of dendritic and cancer cells.

Authors:  Shigeo Koido; Eiichi Hara; Sadamu Homma; Yoshihisa Namiki; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Clin Dev Immunol       Date:  2010-02-18

2.  The liberation of CD44 intracellular domain modulates adenoviral vector transgene expression.

Authors:  Cristhian J Ildefonso; Wesley S Bond; Azza R Al-Tawashi; Mary Y Hurwitz; Richard L Hurwitz
Journal:  J Biol Chem       Date:  2012-08-03       Impact factor: 5.157

Review 3.  Engineering dendritic cells to enhance cancer immunotherapy.

Authors:  Jeanette E Boudreau; Aude Bonehill; Kris Thielemans; Yonghong Wan
Journal:  Mol Ther       Date:  2011-04-05       Impact factor: 11.454

Review 4.  Antigen-specific vaccines for cancer treatment.

Authors:  Maria Tagliamonte; Annacarmen Petrizzo; Maria Lina Tornesello; Franco M Buonaguro; Luigi Buonaguro
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

5.  Antigen-specific polyclonal cytotoxic T lymphocytes induced by fusions of dendritic cells and tumor cells.

Authors:  Shigeo Koido; Sadamu Homma; Eiichi Hara; Yoshihisa Namiki; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  J Biomed Biotechnol       Date:  2010-04-07

Review 6.  Immune therapies for neuroblastoma.

Authors:  Fariba Navid; Michael Armstrong; Raymond C Barfield
Journal:  Cancer Biol Ther       Date:  2009-05-09       Impact factor: 4.742

Review 7.  Immunologic monitoring of cellular responses by dendritic/tumor cell fusion vaccines.

Authors:  Shigeo Koido; Sadamu Homma; Akitaka Takahara; Yoshihisa Namiki; Hideo Komita; Eijiro Nagasaki; Masaki Ito; Keisuke Nagatsuma; Kan Uchiyama; Kenichi Satoh; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  J Biomed Biotechnol       Date:  2011-04-26

Review 8.  Regulation of tumor immunity by tumor/dendritic cell fusions.

Authors:  Shigeo Koido; Sadamu Homma; Eiichi Hara; Yoshihisa Namiki; Akitaka Takahara; Hideo Komita; Eijiro Nagasaki; Masaki Ito; Toshifumi Ohkusa; Jianlin Gong; Hisao Tajiri
Journal:  Clin Dev Immunol       Date:  2010-10-26

Review 9.  Dendritic-Tumor Fusion Cell-Based Cancer Vaccines.

Authors:  Shigeo Koido
Journal:  Int J Mol Sci       Date:  2016-05-26       Impact factor: 5.923

Review 10.  Therapeutic cancer vaccines: past, present, and future.

Authors:  Chunqing Guo; Masoud H Manjili; John R Subjeck; Devanand Sarkar; Paul B Fisher; Xiang-Yang Wang
Journal:  Adv Cancer Res       Date:  2013       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.